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Abstract 
Insomnia in pregnancy is associated with depression, 
preeclampsia, gestational diabetes, and preterm labor. In 
normal pregnancies, maternal plasma melatonin levels 
increase significantly as pregnancy proceeds, reaching 
its peak near term. However, the role of melatonin in 
insomnia during pregnancy is not known. The objective 
of this study was to measure nocturnal saliva melatonin 
levels in pregnant women with and without insomnia. 
Results did not show a significant difference in 
melatonin levels between insomniac (treated and 
untreated) and healthy pregnant women in all trimesters. 
However, sub-group analysis showed significantly lower 
melatonin levels in untreated insomniac pregnancies 
compared to healthy pregnancies and those treated with 
sleep medications. Results of this study confirmed lower 
levels of nocturnal melatonin in untreated pregnancies 
with insomnia. Future research is needed to investigate 
the safety and efficacy of melatonin supplementation for 
the treatment of insomnia in pregnancy, replacing 
psychotropic drugs. 
Keywords: Insomnia depression, preeclampsia, 
gestational diabetes, preterm labor 
Introduction 
Circadian System 
The circadian system is located both in the central 
nervous system in the suprachiasmatic nucleus 
(SCN) of the hypothalamus, and peripheral organs 
such as the heart and liver.
1 
The system plays an 
important role in different physiological 
arrangements and behavior. It is the biological 
clock of the body managing both night and day 
behaviors. The system functions not only 
independent of external stimuli such as ambient 
brightness, but also in a manner dependent on 
external factors such as food intake.
2 
Any 
disruption of the system leads to conditions such as 
sleep disorder, glucose intolerance (diabetes), 
obesity, and ultimately decreased life expectancy.
3
 
Suprachiasmatic Nucleus 
SCN is located in the anterior hypothalamus on top 
of the optic chiasm, next to the third ventricle with 
50,000 neurons.
4 
It is a bilateral structure and is 
activated by light. In other words, it regulates the 
circadian rhythm. Although it is now known that 
circadian rhythm exists in peripheral organs 
independent of the SCN, their function is lost 
without input from SCN. For this reason, SCN is 
called the master circadian clock, or the 
coordinator of the clocks. A circadian clock has a 
24-hour cycle and its most potent stimulus is light 
that is directly projected from the retina to SCN 
through the retino-hypothalamic tract (RHT). The 
indirect pathway of receiving light by the SCN is 
through the intergeniculate tract (GHT). 
Malfunctioning of any of the above pathways 
impairs the phase-shifting and light-dark cycle of 
the circadian system. For example, the light-dark 
cycle is impaired by the RHT pathway damage, 
and phase-shifting is delayed by damage to GHT 
pathway.
1 
Research also shows that the circadian 
clock can shift a phase independent of light with 
other stimuli such as exogenous  melatonin, 
temperature, exercise, and food. For example, 
melatonin supplementation in blind people can 
regulate the circadian clock.
5 
Core body 
temperature also affects the peripheral circadian 
clock but not the SCN.
6 
There are 2 pathways by 
which the SCN manages the circadian clock 
complementing each other: endocrine and neural 
pathways. Circadian clock controls the endocrine 
system including melatonin, cortisol from the 
hypothalamic-pituitary- adrenal (HPA) axis, the 
hypothalamic-pituitary-thyroid (HPT) axis, and 
epinephrine.
7 
The neural pathway includes 
projections from the SCN to the pineal gland 
(Figure 1). 
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Figure 1: The neural pathway between the SCN and 
pineal gland in rats. Reprinted with permission from 
Springer.46 
Pineal Gland 
Description 
The pineal gland had several names over-time 
given its anatomy and function in different 
animals. It was first identified as a different 
cerebral organ a few centuries BC, and was 
initially named “Konareion” for its pine shape, 
similar to lymph nodes. It was then named 
“Glandula Pinealis”, pineal. Later Rene Descartes 
called the gland the “seat of the soul”, coordinator 
of psychophysiological functions of the body. 
Bioassay advances resulted in the discovery of 
pineal “extracts” responsible for lightening frog’s 
skin, which lead to the isolation of melatonin in 
1958. Development of fluorescent techniques 
allowed the measurement of melatonin and 
serotonin, their light-dark cycles and their 
concentrations.
8
 
Structure 
The location and structure of the pineal gland is 
species specific and responds to environmental 
stimuli. The human pineal gland is located at the 
posterior of the diencephalon. It develops in the 
second month of gestation as an invagination of the 
ependymal lining of the diencephalic third 
ventricle, between the habenular and posterior 
commissure. The “pineal stalk” consists of a rostral 
and a caudal lamina surrounded by a pial layer, and 
is suspended in the CSF- filled pineal recess below 
the splenium. Average adult dimensions are 5-
9mm in length, 1-5mm in width, and 3-5mm in 
thickness and the average weight of 100-180mg 
varies in different ages and genders.
8 
Its structure 
is described as two parts. A central core of lobules 
and peripheral neurons along with pinalocytes are 
the main cell types of human pineal gland. 
Pinalocytes are granular shape, and have a nucleus 
and cytoplasmic processes that end in capillaries, 
indicative of an endocrine gland. Neuroglia are 
distributed unevenly in the periphery. Calcareous 
deposits are characteristic of the pineal deposits as 
calcium and magnesium salts on both parenchymal 
and intracellular tissue. Calcareous deposits are 
present from birth and increase in concentration by 
age, starting to decrease in young adulthood. A 
negative correlation was found between the density 
of calcification, age and chronic sleepiness. The 
pineal gland has a rich vascular system receiving 
blood from posterior choroidal arteries deriving 
from cerebral arteries. It lacks an endothelial 
blood-brain barrier, and is sensitive to drugs. The 
gland is innervated with fibres from sympathetic, 
parasympathetic, and central nervous systems. The 
most important pathway is the noradrenergic 
sympathetic pathway neurons which receive input 
from the suprachiasmatic nucleus (SCN) of the 
hypothalamus, which itself receives input from 
retinal ganglion cells.
8
 
Neural Pathway 
The neural pathway regulating the production of 
melatonin in the pineal gland consists of an input 
from the GABAergic system from SCN to a 
subdivision of paraventricular nucleus (PVN), 
which in turn projects to the intermediolateral 
(IML) cell column and, by pre- ganglionic 
adrenergic fibres, to the superior cervical ganglion 
(SCG). The input then reaches  
the pineal gland from SCG by post ganglionic 
adrenergic fibres and releases norepinephrine 
(NE).
35,36 
In the pineal gland, beta adrenergic 
receptors of pinalocytes are stimulated by a subunit 
of G protein coupled receptors that increase 
adenylate cyclase. Ca
++ 
and protein kinase C 
(PKC) are involved in increased beta adrenergic 
activity and stimulation of cAMP potentiated by 
Alpha adrenergic receptors.
37 
The synergistic 
activity of alpha and beta adrenergic receptors 
increases cAMP and production of NAT
38 
(Figure 
2). The rate of melatonin secretion is negatively 
correlated with age 
39
, and dim light melatonin 
onset (DLMO) may not reach the threshold 
concentration, 4 pg/ml, in the elderly.
40 
However, 
concentration is significantly higher in younger 
people.
41 
There are also inter-individual 
differences in timing, duration, and the amount of 
nocturnal hormone secretion
42
, but stability within 
individuals.
43
,
44 
For example, mean melatonin 
production is estimated to be higher in men than 
women at night, 60.7± 24.6 pg/ml and 29.3± 21.8 
pg/ml respectively, p<0.01.
45 
DLMO also occurs 
later in women than in men.
41 
Inter-individual 
differences in melatonin production may be due to 
different metabolism rates.
46
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Figure 2: Adrenergic pathway of melatonin biosynthesis. Reprinted with permission from Elsevier. 47 
Day length affects melatonin secretion as well, so 
there are seasonal variations in the rate of 
nocturnal melatonin, which affects the physiology, 
behavior, and reproduction of some species.
9 
The 
use of artificial light or artificial shortening of 
summer days has been shown to affect the 
secretion of the hormone.
48,49 
Evidence shows 
that the onset of “seasonal affective disorder” is 
related to shorter days and longer nights in fall and 
winter.
50
 
Evidence of melatonin as the circadian phase 
maker comes from studies showing shifts in body 
temperature and sleep timing following melatonin 
administration. Therefore, supplementation with 
melatonin at the right time can adjust circadian 
rhythm after a phase-shift due to shift work, jetlag, 
blindness, or sleep disorders.
51 
Evidence shows 
strong association between melatonin, sleep, and 
body temperature, energy, activity, and mental 
ability. The daytime low level of melatonin and 
high level of cortisol mediate daytime activities. 
Sleep and the dark-light cycle are also mediated by 
changes in melatonin and cortisol levels.
52 
The 
rise of melatonin two hours before bed allows for 
sleep onset, which in turn decreases the nocturnal 
body temperature.
17 
Studies show that blocking 
the beta adrenergic receptors suppresses nocturnal 
melatonin, and increases  body temperature. This 
can be reversed by administering 5 mg melatonin. 
This further confirms the role of melatonin in body 
temperature regulation.
53 
Melatonin levels 
suppressed either pathologically or artificially by 
light lead to insomnia (initiation, maintenance, 
sleep quality).
54 
Figure 3, below shows the 
immediate effect of light exposure on nocturnal 
melatonin levels.
55
 
Figure 3: Effect of light exposure on nocturnal melatonin concentration. Normal pattern of melatonin synthesis 
in dark environment is shown in grey area. Reprinted with permission from Elsevier.55 
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Sleep 
Sleep is defined as a state characterized by a 
reduction in voluntary movement, reduced 
response to stimuli and, ultimately, loss of 
awareness.
52 
Sleep is divided into two parts: non- 
rapid eye movement (NREM) and rapid eye 
movement (REM). NREM itself is divided into 
three stages, which progress to the deeper sleep 
phase, or REM.
56 
Sleep restriction which reduces  
sleep duration affects the structure of sleep.
57 
Regulation of sleep in the brain is a complicated 
process involving several growth factors 
synthesized in response to neural activity. These 
growth factors also affect synaptic efficacy.  
Interlukin-1 (IL-1) and tumor necrosis factor 
(TNF) are the two most important factors in the 
sleep regulation process, released by the 
production of ATP after neurotransmission. They 
increase NREM sleep. Inhibition of these two 
compromises spontaneous sleep and rebound sleep 
after an episode of sleep deprivation. After sleep 
deprivation, IL-1 and TNF concentrations rise. 
However, their over-activation, due to the 
activation of innate immune response, inhibits 
sleep.
58 
Other factors leading to this up regulation 
are light and excessive food intake. IL-1 leads to 
production of corticotropin releasing hormone 
(CRH) which, in turn, inhibits sleep dependent IL-
1 inhibition. CRH also inhibits  IL-1 which causes 
sleep inhibition. Other growth factors involved in 
sleep regulation are nitrous oxide (NO), growth 
hormone releasing hormone (GHRH) and nerve 
growth factor. Nuclear factor kappa B (NFkB), 
adenosine, and prostaglandin. NFkB is activated by 
sleep deprivation. Activation of NFkB leads to the 
activation of adenosine receptor, COX2, and NO 
synthase. COX2 leads to the synthesis of sleep 
promoting prostaglandin D2 (PGD2) and sleep 
inhibiting E2 (PGE2) that inhibits IL-1. Therefore, 
several positive and negative feedback loops are 
involved in sleep regulation or dysregulation. The 
neural system defined above affects the synaptic 
efficacy and downstream pathways that lead to 
wakefulness and consolidation of memory, or 
sleepiness.
59
 
Insomnia 
Insomnia, a form of sleep restriction, is an 
important public health issue.
60 
A large 
population- based study calculated the prevalence 
of insomnia to be 6 - 48% after all diagnostic 
criteria were brought into consideration.
61 
It is 
defined as an inability to initiate sleep, waking up 
during the night, difficulty falling back to sleep, 
and non-restorative sleep.
62 
Delayed sleep phase 
disorder (DSPD) is a disorder of circadian rhythm 
and insomnia, in which the patient has difficulty 
initiating sleep at a normal time, therefore the 
circadian rhythm is delayed when compared to 
healthy individuals.
41 
DSPD patients are able to 
maintain sleep if they go to bed in their favourite 
time, but sleep initiation is delayed. This type of 
insomnia is associated with daytime sleepiness and 
many physiological dysfunctions. Ultimately long 
term DSPD insomnia is associated with 
psychological disorders, substance and alcohol 
abuse, and other neurobehavioral and physiological 
disorders. The prevalence of DSPD is 7-16% in the 
general population.
63 
To further understand the 
etiology of DSPD, nocturnal melatonin levels were 
measured in patients with this disorder and were 
compared with normal sleepers. Results showed 
that DSPD patients have significantly delayed dim 
light melatonin onset (DLMO) by three hours 
when compared with healthy sleepers (Figure 4). 
There was no difference in the duration of 
melatonin secretion but levels did not change 
significantly from DLMO to acrophase in DSPD 
patients.
64 
DLMO is considered an approximate 
night-time threshold of melatonin synthesis and 
secretion. DLMO makes an assessment of the 
circadian rhythm disorder in patients with 
insomnia easier than a provisional assessment. 10 
pg/ml is considered the threshold for plasma 
DLMO and 3 pg/ml for saliva (Figure 6).
65 
Melatonin secretion starts at darkness and is 
suppressed by light, so it is very important to 
measure hormone levels in dim light to determine 
its onset time (DLMO) and to assess circadian 
rhythm in advanced sleep phase disorder (ASPD) 
or delayed in DSPD
41
. DLMO can be measured in 
both blood and saliva. Although DLMO 
measurement is currently used in research, there is 
no approved assay or standards in clinical 
settings.
66 
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Figure 4: Pattern of melatonin secretion in a normal (solid line), ASPS (dashed line), and DSPS (dotted line) 
subject. Reprinted with permission from Elsevier.41 
Figure 5: DLMO levels at 3 pg/ml in saliva. Reprinted with permission from the Journal of Clinical Sleep Medicine.65 
Physiological Impacts of Insomnia 
Chronic medical conditions were reported in 76 - 
83% of the population of different ethnic groups 
due to poor sleep pattern.
67 
Adverse psychological 
and physiological effects of insomnia have a major 
impact on the quality of life of affected 
individuals. Recent experimental and 
epidemiological data have associated insomnia 
with multiple daytime symptoms and chronic 
conditions. Among physiological impacts of sleep 
disorders are metabolic disorders leading to obesity 
and type 2 diabetes.
68 
Insufficient sleep 
contributes to weight gain via excessive food 
intake associated with increased energy 
expenditure. Studies show that sleep restriction 
reduces daytime leptin while increasing daytime 
ghrelin. These hormonal changes lead to increased 
hunger and appetite.
69 
Increased food intake is 
beyond the energy needed leading to weight 
gain.
70 
Glucose intolerance increases and its 
clearance decreases upon sleep loss due to an 
impaired metabolism system.
71 
Studies suggest 
the potential benefit of recovery sleep.
70
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Hypertension is among other physiological side 
effects of sleep restriction. It is shown in several 
studies that insomnia and short sleep duration is 
associated with hypertension. Duration of sleep is a 
predictor of the severity of hypertension.
72 
When 
adrenocorticotropic hormone (ACTH) and cortisol 
levels were compared in insomniac patients and 
normal sleepers in a lab environment, results were 
elevated nocturnal levels of those two hormones 
leading to hyper-activation of hypothalamic-
pituitary-adrenal axis. This, in turn, causes several 
pathological consequences, such as 
hypertension.
73 
Obesity, increased insulin 
resistance and cardiovascular diseases are 
associated with elevated levels of ACTH and 
cortisol. Irwin et al. showed an increase in 
nocturnal norepinephrine in insomniac patients 
when compared to depressed and healthy 
individuals. This may be an indication of increased 
sympathetic activity, exhibited by increased heart 
rate, body temperature and metabolic rate.
74 
Other 
studies also showed coronary artery disease 
mortality after chronic insomnia in middle-aged 
men and women.
75
 
Impacts of Insomnia in Pregnancy 
There are physiological and psychological 
consequences following insomnia in pregnancy. 
Glucose intolerance and gestational diabetes 
mellitus (GDM) are amongst the physiological 
impacts of insomnia in pregnancy. The prevalence 
of GDM in the US is approximately 7%, affecting 
200,000 women every year. Risk increases by 
obesity and/or type 2 diabetes (T2D).
40 
Earlier it 
was mentioned that insomnia is a risk factor for 
type 2 diabetes. As a result, insomnia and T2D 
may increase the risk of a pregnancy to develop 
GDM. In a cohort study following up pregnant 
women from early pregnancy with their sleep 
duration, it was found that women with shorter 
sleep duration are at 1.86 fold increased risk for 
development of gestational diabetes.
41 
GDM 
adversely affects both maternal and fetal health and 
pregnancy outcomes. Mothers with GDM are at 
increased risk for cardiovascular disease and 
metabolic dysfunction.
42 
GDM put the pregnancy 
at risk for pre-eclampsia, preterm labor and 
caesarean section due to the accumulation of 
excessive amniotic fluid, and infection.
43 
In 
addition to maternal risks associated with GDM, 
children of diabetic mothers are at increased risk 
for macrosomia, related birth injuries, respiratory 
problems, neonatal hypoglycemia, and jaundice.
44
 
Hypertension is one of the other physiological 
impacts of insomnia in individuals. In a pregnancy 
prospective cohort study, mean diastolic, systolic 
and mean arterial pressures were measured. It was 
found that systolic blood pressure is highest in 
those who sleep less than six hours at night in both 
first trimester and third trimester, a 1.62 and 4.41 
fold increase respectively. Also, diastolic blood 
pressure blood pressure was highest in short time 
sleepers in both first and third trimesters, 1.85 and 
3.52 fold increase respectively. Mean arterial 
pressure was significantly higher in both short and 
long sleep durations.
 45 
In the previous chapter 
mechanisms responsible for hypertension 
associated with insomnia have been explained. 
Changes in body’s hemodynamics such as 
temperature, heart rate and hyper-activation of the 
HPA axis are all factors in increased risk for 
hypertension. 
Circadian system dysregulation and insomnia is 
now known to be a risk factor in depression and 
mood disorders in pregnancy. In line with this, 
studies investigated plasma melatonin levels in 
pregnant women with and without depression. 
Levels were measured at baseline, synthesis onset, 
and offset times. It was found that daytime 
melatonin levels are significantly higher in 
depressed pregnant women, while night time levels 
were significantly lower when compared to healthy 
pregnancies. Melatonin synthesis onset time and 
offset time were also significantly earlier in 
depressed pregnant women. Second finding of this 
study was that the number of previous  episodes of 
depression was negatively correlated with 
melatonin offset time r=-0.66. 
Therefore, previous episodes of depression may be 
a risk factors in earlier onset and offset times of the 
hormone production and its low levels in 
pregnancy. Depression disorders in pregnancy are 
explained by loss of sensitivity of melatonin 
receptor to estradiol and progesterone levels 
(Figure 6). Therefore, rise in gonadal hormone in 
healthy pregnancy results in an increase in 
melatonin levels but not in depressed 
pregnancies.
46
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Figure 6: Relationship between melatonin levels and estradiol and progesterone in healthy and depressed pregnant 
women.Reprinted with permission from Journal of women’s health, Mary Ann Liebert Inc147 
Rationale 
Sleep is important for the physiological and 
psychological wellness, quality of life, and overall 
well-being. Primary insomnia or insomnia 
secondary to depression and anxiety are major 
health issues amongst pregnant women.
74 
Elevated blood pressure,
45 
gestational diabetes,
41 
preterm birth,
48 
preeclampsia, prolonged labor, 
increased cesarean section rates, prenatal and post- 
partum depression are amongst adverse pregnancy 
outcomes associated with sleep disorders in 
pregnancy.
75 
Poor sleep quality and quantity in the 
last month of pregnancy are associated with post-
partum depression.
91
 
Although there is a lot of epidemiological data on 
the impact of insomnia on pregnancy and its 
outcome, little is known about the pathophysiology 
involved. Understanding the pathophysiology and 
etiology of sleep helps address the issue with better 
treatment regimen. 
Physiological and psychological impacts of 
untreated insomnia on maternal and fetal health 
and on pregnancy outcome lead to more in-depth 
investigation of the disorder and treatment options. 
Since melatonin is a naturally occurring hormone 
in our body and is responsible for the sleep-wake 
cycle and circadian rhythm, it is very important to 
find out if pregnant women with insomnia have 
lower levels of the hormone. To our knowledge no 
study has examined the effects of melatonin levels 
on the pathophysiology of insomnia. 
In normal pregnancies, an increase in nocturnal 
maternal melatonin levels after 24 weeks to term 
has been documented.
28 
Maternal and umbilical 
cord melatonin levels are highly and positively 
correlated when measured at term, suggesting that 
the hormone freely crosses the human placenta.
30 
Local synthesis of the hormone by the human 
trophoblast have been identified as indication of 
autocrine, paracrine, intracrine and endocrine 
function of the hormone.
28,35 
However, there is 
still a question of whether placental melatonin 
levels play a role in the sleep patterns of pregnant 
women. 
The rationale for doing this study was to find out if 
salivary melatonin levels in pregnant women with 
insomnia were lower than in healthy pregnancies. 
An understanding of the melatonin levels in 
insomniac pregnancies aids in choosing a better 
treatment such as melatonin as a natural hormone 
therapy as opposed to psychotropic medications 
and their potential risk for the health of pregnancy 
and the unborn child. If lower melatonin levels are 
found it leads us to further research the safety and 
efficacy of melatonin supplementation to treat 
insomnia in pregnancy (without the side effects of 
pharmacotherapy on both mother and fetus/baby, 
which are explained in detail earlier in this paper). 
Melatonin is a natural hormone, and it was 
explained above that it has a high efficacy profile 
in treating insomnia with minimal side effects in 
non-pregnant individuals. To our knowledge there 
is no safety and efficacy study on the hormone in 
pregnancy. The rationale behind choosing saliva 
measurement was that it is non-invasive, and 
patients can collect the samples in the convenience 
of their home before bed. Melatonin was measured 
three times in pregnancy − at the end of all 
trimesters to get a better understanding of the 
pattern of increase, in each patient and between 
patients. 
Objective of study 
The objective of this study was to measure and 
determine salivary melatonin levels in pregnant 
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women with insomnia, treated or untreated, and to 
compare their levels with healthy pregnant women 
in all trimesters of pregnancy. 
Methods 
Measuring Melatonin in Saliva 
Saliva 
Healthy individuals produce 500-1500 ml of saliva 
per day, or 0.5 ml/minute salivary output, and 
composition may be different in terms of viscosity, 
ions and protein concentrations. The flow of the 
saliva depends on autonomic stimulation. 
Parasympathetic stimulation results in a large flow, 
with low levels of inorganic and non-protein 
organic compounds, such as cholesterol, uric acid, 
glucose, bilirubin, and creatinine. Sympathetic 
stimulation results in a small flow high in 
inorganic compounds such as K
+ 
and proteins. 
Compounds are released into saliva by different 
means, such as passive diffusion for lipophilic 
compounds, active transport and ultrafilteration 
through gap junctions.
76
 
Saliva Melatonin and its Interactions 
Melatonin transfers into saliva by passive 
diffusion.
76 
Composition of the saliva is affected 
by food intake, increasing the release of total 
proteins. Caffeine should be avoided 12-24 hours 
before saliva sampling because it stimulates the 
activity of CYP 1A2.
77 
Banana with low 
melatonin content is shown to increase urinary 
melatonin metabolite after consumption. This can 
be explained by the rate of absorption or 
metabolism of melatonin due to CYP1A2 
polymorphism. Chocolate increases melatonin 
concentration by its flavonoid content.
178 
Some 
drugs such as NSAIDS (ibuprofen, naproxen, 
diclofenac, ketorolac, etc.) may also reduce 
melatonin concentrations by inhibiting 
prostaglandin and COX-2.
79 
Therefore, in the 
current study, patients were instructed to avoid the 
above mentioned to prevent any interaction with 
saliva melatonin levels. 
Measuring Melatonin in Saliva 
Salivary measurement of melatonin is now a 
practical and reliable tool for diagnosis of the 
condition and research purposes. Saliva melatonin 
as a circadian phase maker is validated and 
compared to plasma levels. There is a significant 
positive correlation between saliva and plasma 
melatonin onset r=0.64, and saliva and plasma 
acrophase concentrations, r=0.83 with saliva levels 
being one-third of plasma’s (Figure 7). 80 Saliva 
sampling should be done in dim light and taken 
every 30-60 minutes for at least one hour to 
determine its onset.
81 
Reliability of saliva 
melatonin measurement to determine dim light 
melatonin onset (DLMO) was assessed. Results 
showed that saliva measurement of melatonin 
levels is valid, and it is a reliable tool for the 
measurement of hormones.
81 
This was further 
investigated by comparing in-home methods to 
laboratory measurements. Patients with insomnia 
were instructed to collect saliva samples at home 
and the following evening saliva samples were 
collected in the lab under lab conditions. It was 
found that at-home saliva melatonin levels are 
positively correlated with in-lab measurements 
r=0.85. However, a delay of approximately forty 
minutes was seen with the in- home method. This 
study confirmed the previous work that in-home 
saliva melatonin measurement is practical and 
valid to determine DLMO and to assess circadian 
rhythm (Figure 7).
66
 
 
Figure 7: Relationship between plasma and saliva melatonin levels r=0.64. Reprinted with permission from SAGE 
publications.180 
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Figure 8: Relationship between in-home saliva melatonin and in-lab measurement, r=0.8. Reprinted with 
permission from Elsvier Limited.66 
Study Methodology 
Saliva collection was done three times during 
pregnancy; at 12 -14 weeks, 24-26 weeks, and 34-
36 weeks. I was interested to know the pattern of 
melatonin rise from the beginning of pregnancy in 
all three groups described above. Plasma melatonin 
levels were measured in all trimesters
29
. 
Participants collected saliva samples 3 times every 
30-60 minutes, in dim light, starting at least 1 hour 
prior to bedtime. Therefore, in total there were 9 
saliva samples from each participant. No chocolate 
or bananas, alcohol, caffeine, or drinks with 
artificial colorants should have been taken on the 
day of sampling. No aspirin or medicines 
containing ibuprofen, would be taken on the day of 
sampling. The participant needed to remain in dim 
light during the sampling hours with a night light 
or a low wattage lamp. They should not have sat 
closer than 6 feet to a TV; and if using a 
computer/laptop/tablet, they should have adjusted 
the contrast to low. To avoid contamination with 
food, participants needed to finish their main meal 
at least 30 minutes before sampling time and to 
brush their teeth without toothpaste then rinse with 
water 10 minutes before sampling.
80 
For saliva 
sampling a cotton swab was used, which was 
chewed or held in the mouth for 1-2 minutes, and 
then placed in a vial when soaked enough. 
Participants documented each sample time on a log 
provided to them along with the duration of staying 
in dim light. Participants were instructed to 
refrigerate or freeze their saliva samples within 30 
minutes of sampling and mail them back in a cold 
box within 1-3 days. All storage and shipment 
accessories were provided to participants. The 
saliva samples were tested for melatonin levels 
using the enzyme-linked immunosorbent assay 
(ELISA) method in the Motherisk lab. 
Statistical Analysis 
All statistical analysis was done with student SPSS 
version 23. All data is presented in mean ± SEM. 
In order to compare melatonin concentrations 
between pregnant women with insomnia either 
treated or untreated (combined in one group) with 
healthy pregnant women a t-test was used. The 
null-hypothesis was that there was no difference in 
melatonin levels in insomniac pregnant women and 
healthy pregnancies. 
For sub-group analysis, one-way ANOVA was 
used. Subgroups included pregnant women with 
treated insomnia, pregnant women with untreated 
insomnia and healthy pregnant women.In the 
general linear model, repeated measure analysis 
was used to compare the pattern of increase of 
melatonin levels in all two groups of untreated 
insomniacs, treated insomniacs and healthy 
subjects. Alpha was set at p<0.05 in all statistical 
analysis. 
Results 
In the first group, Exposed, a total of 24 people 
were recruited. 13 were lost to follow up. They did 
not respond to emails or phone calls after the ICF 
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was signed. Two had miscarriages and 
automatically were excluded from the study. One 
patient provided a very small amount of saliva 
sample that was not measurable. One patient’s 
saliva melatonin measure was an outlier, and was 
deleted from the analysis. In the first trimester 
seven samples were used in (T1) melatonin 
measurement. In the second trimester (T2). This is 
while one patient withdrew after T1, but one 
patient was recruited in the second trimester due to 
her severe insomnia symptoms. In the third 
trimester (T3) measurement, there were five 
samples because two patients withdrew after T2. 
In the second group, Disease-match, 19 people 
were recruited. Six were lost to follow up, and 13 
samples were received for the T1 measurement. 
For the T2 measurement there were 12 samples, as 
one patient withdrew after T1. For the T3 
measurement there were 9 samples because one 
patient withdrew. Two other patients had sampling 
dates much later than the expected end date of 
study. 
In the third group, Healthy, a total of 28 people 
were recruited. 7 were lost to follow up, two had 
miscarriages and one provided small amount of 
saliva that was not measurable. A total of 18 
samples were used for the T1 measurement. For 
the T2 there were 11 samples. There were 4 
withdrawals, 2 miscarriages, and one was lost to 
follow up in T2. In T3, there were 12 samples, 
because one patient that was lost to follow up in T2 
came back and continued the study (Figure 9). 
 
Figure 9: Study population saliva sample size per group per trimester. 
 
Mean (SD) age was not significantly different 
among the groups, 35.43±3.7, 35.54±4.4, 
33.73±3.7, respectively. Ethnic background, 
marital status, education, occupational status, 
number of pregnancies (gravidity), number of live 
children (parity), spontaneous abortions (SA), 
therapeutic abortion (TA), ectopic pregnancies 
(Ect), pre-pregnancy BMI, third trimester BMI, 
and total weight gain. 
Disease Characteristics of the Insomnia Group 
Five patients in the Exposed group suffered from 
insomnia only. One patient had insomnia, 
depression, anxiety and attention deficit disorder 
(ADD). One patient had insomnia, is bipolar, and 
had mania. One patient had insomnia and anxiety, 
and one patient suffered from insomnia and 
depression. 
In the Disease-match group, eight patients suffered 
from insomnia only. One patient had insomnia, 
depression, and anxiety. One patient had insomnia 
and anxiety, two patients had insomnia and 
depression. 
All nine patients in the Exposed (treated) group 
took medications for either sleep issues or 
comorbid symptoms such as depression and 
anxiety. Five patients took one or combinations of 
zopiclone, quetiapine, lorazepam, dimenhydrinate, 
and progesterone as a sleep aid. One patient took a 
combination of bupropion, amitriptyline, 
lisdexamphetamine, and clonazepam for insomnia, 
depression/anxiety, and ADD. Trazodone and 
aripiprazole were taken by another patient for 
bipolar disorder, mania and insomnia. Zopiclone, 
duloxetine and trazodone were used in 
combination for insomnia and comorbid anxiety. A 
combination of bupropion and quetiapine was taken for 
insomnia and comorbid depression (Table 1). 
Exposed: 
Lost F/U (13) 
Miscarriages (2) 
Small  amnt (1) 
Final Exposed Gr. 
Subjects 
T1: N=7 
T2: N=7 
T3: N=5 
  Disease-Match: 
Lost F/U (6) 
Final Disease-match 
Gr. Subjects 
T1: N=13 
T2: N=12 
T3: N=9 
Healthy: 
Lost F/U (7) 
Miscarriages (2) 
Small amount (1) 
Final Healthy Gr. 
Subjects 
T1: N=18 
T2: N=11 
T3: N=12 
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Condition Exposed 
Group N=9 
Disease-Match 
Group N=12 
Insomnia Only 5(55%) 8(67%) 
Insomnia with 
other psychiatric 
comorbidities 
4(44%) 4(33%) 
Table 1: Disease composition of exposed and 
disease-match group. 
T-tests compared insomniac (exposed and disease-
match) pregnant women (N=20) with healthy 
pregnant women. It was found that mean melatonin 
levels in all three trimesters were not significantly 
different between the two groups, p=0.4, p=0.9, 
p=0.1 for T1, T2, and T3 respectively (Table2) 
(Figure 10). 
 
 
 
 
 
 
 
 
 
Table 2: Descriptive statistics and t-test results. No significant difference found between the groups in all 
trimesters. T1: first trimester, T2: second trimester, T3: third trimester, Insom: insomnia, H: healthy  
 
Figure 10: Comparison of melatonin levels in both groups in all trimesters. 
Sub-group analysis by one-way ANOVA (Table 3) showed that Disease-match (untreated) insomniac pregnant 
women have significantly lower melatonin levels (p=0.04) in the third trimester (mean (pg/ml)=8.2±1.33 SEM), 
when compared to the treated (mean (pg/ml) = 16.8±3.1 SEM) and Healthy pregnant women (mean 
(pg/ml)=17.4 ±3.5 SEM). No significant difference was found in melatonin levels among the groups in the first 
  
Groups 
 
N 
Mean 
melatonin 
pg/ml 
 
Std. 
Deviation 
Std. Error 
Mean 
 
P-value 
T1 Insom. 
H 
20 
18 
9.4 
11.0 
6.1 
6.3 
1.3 
1.5 
0.4 
T2 Insom. 
H 
19 
11 
11.9 
11.9 
12.6 
11.7 
2.9 
3.5 
0.9 
 
T3 
Insom. 
H 
14 
12 
11.3 
17.4 
6.5 
12.0 
1.7 
3.4 
0.1 
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trimester with the following means: Exposed: 8.9±1.6 pg/ml, Disease-match: 9.7±2.0 pg/ml, Healthy: 11.0±1.5 
pg/ml. Pairwise comparison showed significant lower melatonin levels in Disease-match compared to healthy 
group (p=0.03) in the third trimester. Pairwise comparison also found Disease-match group’s melatonin levels 
significantly lower (7.4±2.1 pg/ml) compared to the Exposed group (19.5±6.25 pg/ml) in the second trimester, 
p=0.03. 
 
 
Trimester
 Group
s 
 
 
N 
Mean 
Melatoni
n pg/ml 
 
 
Std. 
Deviation 
 
 
Std. Error 
 
 
P-value 
T1 EXP 7 8.9 4.3 1.6 0.7 
DM 13 9.7 7.1 1.9  
H 18 11.0 6.3 1.5 
T2 EXP 7 19.5 16.5 6.2  
 
0.2 
DM 12 7.4 7.4 2.1 
H 11 11.9 11.7 3.5  
T3 EXP 5 16.8 6.9 3.1  
 
0.04 
DM 9 8.2 4.0 1.3 
H 12 17.4 12.0 3.4  
Table 3:One-way ANOVA analysis of the three groups in all trimesters. Significant difference observed only in 
third trimester. EXP: exposed group, DM: Disease-Match, H: Healthy, T1: first trimester, T2: second trimester, 
T3: third trimester. 
Repeated measure analysis was performed for all three groups separately, investigating the pattern of change in 
melatonin levels in all trimesters as secondary observation. No significant change was found in all groups when 
all trimesters were compared, p=0.1, p=0.3, p=0.1 for the Exposed, Disease-match, and Healthy groups 
respectively (Table 4) (Figure 11). 
Groups Trimester Mean, pg/ml SD N sig. 
 T1 10.7 4.1   
EXP T2 26.0 19.6 4 ns 
 T3 18.6 6.4   
 T1 9.3 7.6   
DM T2 5.8 2.7 9 ns 
 T3 8.2 4.0   
 T1 9.7 5.0   
H T2 11.9 11.7 11 ns 
 T3 19.6 19.6   
Table 4: Repeated measure analysis did not show a significant rise of melatonin levels in all trimesters. Exp: 
exposed, DM: disease-match, H: healthy. ns: non-significant 
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Figure 11: Dot plot of repeated measure analysis of melatonin levels in all trimesters. EXP: exposed, DM: 
disease-match, H: healthy. T1: first trimester, T2: second trimester, T3: third trimester. 
Discussion 
Both groups with insomnia were associated with 
comorbid mental disorders. 
Melatonin levels in treated women with 
psychotropic drugs were similar to healthy 
controls. A non-significant difference in melatonin 
levels in insomniac pregnancies (Exposed and 
Disease- match combined group) compared with 
Healthy subjects is indicative of higher melatonin 
level in the exposed group due to the effects of 
sleep medications. All nine patients in the Exposed 
(treated) group took medications for either only 
sleep issues or comorbid symptoms such as 
depression and anxiety. Five patients took one or 
combinations of zopiclone, quetiapine, lorazepam, 
dimenhydrinate, and progesterone as a sleep aid. 
One patient took a combination of bupropion, 
amitriptyline, lisdexamphetamine, and clonazepam 
for insomnia, depression/anxiety and ADD. 
Trazodone and aripiprazole were taken by another 
patient for bipolar, mania, and insomnia. 
Zopiclone, duloxetine and trazodone were used in 
combination for insomnia and comorbid anxiety. A 
combination of bupropion and quetiapine was 
taken for insomnia and comorbid depression. 
Amitriptyline decreases sleep latency while 
treating depression symptoms. It also increases 
melatonin synthesis by increasing NAS (N-acetyl 
transferase) in the pineal gland.
84 
SSRIs cause 
increased sleep latency, REM suppression and 
frequent waking up during the night. As a result, 
pharmacotherapy addressing the treatment of 
insomnia should be considered with SSRIs.
85 
This 
is in conflict with a clinical study where duloxetine 
was shown to increase 6- sulphatoxymelatonin 
(aMT6s) levels after treatment.
19 
Duloxetine was 
used in one patient for anxiety and trazodone and 
zopiclone were used concomitantly to improve 
sleep. Zopiclone has no effect on melatonin 
concentration when compared to zalplona placebo 
and a non- benzodiazepine hypnotic in rats.
20 
Similar results have been found in healthy 
volunteers following acute and subchronic 
administration of zopiclone.
121 
A sleep-inducing 
effect may be due to its hypnotic properties. 
Increased melatonin levels and improved sleep 
with trazodone has been documented in clinical 
studies.
24
,
25 
Bupropion is associated with 
increased REM (rapid eye movement) sleep,
85 
however, a meta-analysis found bupropion was one 
of the antidepressants that caused insomnia the 
most often (Figure 12).
86
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Figure 12: Ascending odds ratios for antidepressants and association with insomnia. Reprinted with permission 
from Wolters Kluwer Health, Inc.86 
Low dose quetiapine is shown to have a non-
significant effect on melatonin level but 
significantly reduces nocturnal cortisol levels.
26 
A 
lower cortisol level is associated with a higher 
melatonin level.
27
 
Melatonin levels in women with untreated 
insomnia have been low throughout pregnancy. 
This indicates the potential role of melatonin in 
sleep regulation. Moreover, it further shows the 
effect of psychotropic medications on sleep and 
improvement of symptoms which was observed in 
treated group. Significant lower levels of 
melatonin observed in the untreated (disease-
match) group in the third trimester of pregnancy, 
compared to the Exposed and Healthy groups, are 
an indication of the negative role insomnia and 
sleep disorders can play in modulating melatonin 
levels. 
There were limitations in this study. First and most 
important was a lack of power due to small sample 
size. Unmeasured patient compliance was another 
challenge in this study. Whether patients followed 
all the instructions they were given from staying in 
dim light to refrain from food and drugs listed in 
the instruction sheet were not measured. It was 
also difficult recruiting pregnant women with 
insomnia who may also suffer from other 
comorbid psychiatric conditions. Furthermore, 
retaining these patients for the duration of 
pregnancy was another challenge in this study. 
Therefore, we stopped the study without reaching 
our optimal calculated sample size. 
This study opened the door to future research on 
the important role of melatonin in the regulation of 
sleep in pregnancy. More research is needed to 
confirm the validity of salivary method of 
melatonin measurement during pregnancy. 
Assessment of efficacy and reproductive safety of 
melatonin supplementation in the treatment of 
insomnia during pregnancy is an important subject 
of future investigations. 
Conclusion 
Presently, pregnant women suffering from 
insomnia are treated with pharmacotherapy, most 
commonly with sedative hypnotics, 
benzodiazepines, antihistamines, and 
antipsychotics. Side effects vary from daytime 
sleepiness to dependence. Many studies looked at 
the benefits and risks associated with sleep 
medications in pregnancy. Fetal risks associated 
with some of these medications have been 
confirmed in the studies. Side effects include low 
risk oral cleft palate, withdrawal symptoms after 
birth, preterm birth, and low birth weight. 
118,188-
190 
Meanwhile, studies examined the efficacy of 
the exogenous melatonin in treating sleep 
disorders. A recent meta-analysis on the efficacy of 
melatonin for the treatment of insomnia showed a 
significant decrease in sleep latency, increased 
sleep time, and a significant positive effect on 
sleep quality.
118 
Results from an open-labeled 
long-term study showed the efficacy and safety of 
prolonged-release melatonin (2mg) without any 
withdrawal symptoms. Results also showed that 
long term melatonin treatment is not associated 
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with suppression of endogenous secretion of the 
hormone as levels measured in urine two weeks 
after discontinuation. No dependence, relapse of 
symptoms, or withdrawal symptoms have been 
reported after discontinuation of treatment.
91 
Pilot 
studies at this time are investigating the role of 
antenatal melatonin administration as an 
antioxidant in late pregnancies to prevent or treat 
IUGR and preeclampsia.
92, 93 
The prospect of 
treating pregnant women with insomnia with the 
natural sleep hormone melatonin has received very 
little attention. 
This study confirmed the lower saliva levels of 
melatonin in pregnant women with untreated 
insomnia. Therefore, melatonin supplementation 
may be considered an intervention for insomnia in 
pregnancy. Melatonin is inexpensive, is available 
over-the counter and it has a low side effect 
profile. This study confirmed a need for future 
research to introduce melatonin as a natural 
hormone therapy for insomnia. The results of this 
study may have a significant positive effect on the 
quality of life and health of many pregnant women 
worldwide currently on sleep medication who have 
no choice but to continue pharmacotherapy to 
maintain a stable mental and physical health during 
pregnancy. 
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